A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America

1. Raje, N.
2. Roodman, G.D.
3. Willenbacher, W.
4. Shimizu, K.
5. García-Sanz, R.
6. Terpos, E.
7. Kennedy, L.
8. Sabatelli, L.
9. Intorcia, M.
10. Hechmati, G.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1080/13696998.2018.1445634 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus